Abstracts tagged "Infection"

Abstract Number: 2079 • 2016 ACR/ARHP Annual Meeting
Incidence and Risk of Pneumocystis Jirovecii Pneumonia Following Rituximab Treatment in Granulomatosis with Polyangiitis in the United States: An Analysis from a National Database
Sirada Panupattanapong¹, Anthony R. French², Andrew J. White², Margaret A. Olsen³, Maya Rendulic⁴ and Mary E. Hartman⁵, ¹Pediatrics, Division of Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, ²Division of Pediatric Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, ³Division of Infectious Disease, Washington University School of Medicine, St. Louis, MO, ⁴Center for Administrative Data Research, Washington University School of Medicine, St. Louis, MO, ⁵Division of Pediatric Critical Care Medicine, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO
Background/Purpose: Pneumocystis Jirovecii pneumonia (PJP) is a life-threatening complication in granulomatosis with polyangiitis (GPA). Guidelines from EULAR for ANCA-associated vasculitis (AAV) recommend institution of PJP…
Abstract Number: 689 • 2016 ACR/ARHP Annual Meeting
Relationship Between Infliximab Serum Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis
Theodora Bejan-Angoulvant¹, David Ternant², Fadela Daoued³, Frédéric Medina³, Louis Bernard⁴, Saloua Mammou³, Gilles Paintaud² and Denis Mulleman⁵, ¹Service de Pharmacologie Clinique, CHRU de Tours, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, ²Laboratoire de Pharmacologie-Toxicologie, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, ³Service de Rhumatologie, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, ⁴Service des Maladies Infectieuses, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, ⁵Service de Rhumatologie, Rheumatology department, François-Rabelais University, CNRS 7292, CHRU de Tours, Tours, France
Background/Purpose: Tumour necrosis factor alpha inhibitors are effective in reducing inflammation in rheumatic diseases while increasing the risk of infections. We aimed to study the…
Abstract Number: 2310 • 2016 ACR/ARHP Annual Meeting
The Predictive Risk Factors for Complication of Infection during the Treatment for Inflammatory Myopathies Complicated with Interstitial Lung Disease
Yumiko SUGIYAMA^1,2, Maasa Tamura^1,2,3, Ryusuke Yoshimi^1,2, Naoki Hamada^1,2, Hideto Nagai^1,2, Yuko Tatekabe^1,2, Naomi Tsuchida^2,4, Yutaro Soejima^1,2, Yosuke Kunishita^2,4, Daiga Kishimoto^1,2, Hiroto Nakano^1,2, Reikou Kamiyama^1,2, Kaoru Minegishi^2,5, Yukiko Asami^1,2, Yohei Kirino^2,4, Shigeru Ohno^2,5 and Hideaki Nakajima¹, ¹Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Y-CURD Study Group, Yokohama, Japan, ³Nagaoka Red Cross Hospital, Nagaoka, Japan, ⁴Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan, ⁵Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Interstitial lung disease (ILD) is one of the predominant causes of death in polymyositis/dermatomyositis (PM/DM). We have already reported that low PaCO2 and interstitial…
Abstract Number: 773 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Severe Infections in Rituximab Treated Patients: Comparison of Systemic Lupus Erythematosus and Inflammatory Myositis
Cristiane Medeiros¹, Luciana Seguro², Fernando Henrique Carlos de Souza², Nadia E Aikawa³ and Eloisa Bonfa⁴, ¹Rheumatology, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Pediatric Rheumatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology Divison, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil
Background/Purpose: The use of Rituximab (RTX) in patients with autoimmune diseases has been associated with an increased incidence of infection and risk factors for this…
Abstract Number: 2543 • 2016 ACR/ARHP Annual Meeting
Impact of Concomitant Methotrexate Administration on the Risk of Infections Among Rheumatoid Arthritis Patients Treated with Anti-TNF in Real-World
John Kelsall¹, Anna Jaroszynska², Louis Bessette³, Raman Joshi⁴, Isabelle Fortin⁵, Jacqueline Stewart⁶, Keltie Anderson⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Francois Nantel¹⁰, Karina Maslova¹¹, Brendan Osborne¹², Cathy Tkaczyk¹² and Allen J Lehman¹¹, ¹Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Private practice, Burlington, ON, Canada, ³Rheumatology, CHUL de Quebec, Quebec, QC, Canada, ⁴William Osler Health Centre-Brampton Civic Hospital, Brampton, ON, Canada, ⁵Centre de Rhumatologie De l’Est du Quebec, Rimouski, QC, Canada, ⁶Penticton Regional Hospital, Penticton, BC, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Methotrexate (MTX) is routinely used among rheumatoid arthritis (RA) patients treated with anti-TNF agents to enhance treatment efficacy and minimize the dose of biologic…
Abstract Number: 1000 • 2016 ACR/ARHP Annual Meeting
Subclinical Cytomegalovirus Viremia Is Associated with Increased Nosocomial Infections and Prolonged Hospitalization in Patients with Systemic Autoimmune Diseases
John McKinnon¹, Junying Zhou², Jenna Hudy¹, Sara Hegab¹ and Kathleen Maksimowicz-McKinnon³, ¹Henry Ford Hospital, Detroit, MI, ²Infectious Diseases, Henry Ford Hospital, Detroit, MI, ³Rheumatology, Henry Ford Hospital, Detroit, MI
Background/Purpose: Both subclinical cytomegalovirus (CMV) viremia and CMV disease have been associated with adverse outcomes in select immunosuppressed populations, including an increased incidence of other…
Abstract Number: 2575 • 2016 ACR/ARHP Annual Meeting
The Presence of Staphylococcal Toxins in the Urine of Patients with Rheumatoid Arthritis
Laura Grace¹, Marwan Bukhari², Robert Lauder³, Lisa Bishop^4,5 and Adam Taylor¹, ¹Lancaster Medical School, Lancaster University, Lancaster, United Kingdom, ²Royal Lancaster Infirmary, Lancaster, United Kingdom, ³Biomedical & Life Sciences, Lancaster University, Lancaster, United Kingdom, ⁴Biomedical and Life Sciences, Lancaster University, Lancaster, United Kingdom, ⁵University Hopsitals of Morecambe Bay NHS Trust, Lancaster, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is a disease of unknown etiology;with a pathogenesis that is due to a mixture of genetic, immunological and environmental factors. A…
Abstract Number: 1003 • 2016 ACR/ARHP Annual Meeting
Ultrasonography Changes during the Course of Septic Arthritis ARE Associated with Functional Outcome
Emeline Gaigneux¹, Grégoire Cormier², Oriane Merot³, Yves Maugars⁴ and Benoit Le Goff⁴, ¹rheumatology unit, Nantes University Hospital, Nantes, France, ²rheumatology unit, Hospital, La roche sur Yon, France, ³rheumatology unit, Hospital, Saint Nazaire, France, ⁴Rheumatology, Nantes University Hospital, Nantes, France
Background/Purpose: The main goal of this study was to describe the US changes observed during the course of septic arthritis and their association with…
Abstract Number: 2618 • 2016 ACR/ARHP Annual Meeting
Risk Factors of Severe Infections in Patients with Rheumatoid Arthritis Treated with Tocilizumab in the French Registry Regate (REGISTRY –ROACTEMRA)
Jacques Morel^1,2, Arnaud CONSTANTIN³, Gabriel Baron⁴, Emmanuelle Dernis⁵, Rene-Marc Flipo^6,7, Stephanie Rist Bouillon⁸, Bernard Combe⁹, Jacques-Eric Gottenberg¹⁰, Thierry Schaeverbeke^11,12, Martin Soubrier¹³, Olivier Vittecoq¹⁴, Maxime Dougados¹⁵, Alain Saraux¹⁶, Xavier Mariette¹⁷, Philippe Ravaud¹⁸ and Jean Sibilia¹⁹, ¹Montpellier University Hospital, Montpellier, France, ²Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ³Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ⁴Hôpital Hôtel Dieu, Paris, France, ⁵Service de Rhumatologie, Centre Hospitalier, Le Mans, France, ⁶Rheumatology, Hopital R Salengro CHRU, Lille, France, ⁷Rheumatology, University Hospital, Lille, France, ⁸Rhumatologie, Hopital La Source, La Source, France, ⁹Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ¹⁰Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹¹Bordeaux University Hospital, Bordeaux, France, ¹²Rheumatology, CHU Bordeaux, Bordeaux, France, ¹³Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹⁴Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, ¹⁵Paris Descartes University, Paris, France, ¹⁶Rheumatology, Brest University Medical School Hospital, Brest, France, ¹⁷Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France, ¹⁸Centre d’Épidémiologie Clinique, AP-HP (Assistance Publique des Hôpitaux de Paris), Hôpital Hôtel Dieu, Paris, France, ¹⁹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Observational studies have already reported the risk of serious infections in rheumatoid arthritis (RA) treated with tocilizumab but in limited samples. The aim of…
Abstract Number: 1193 • 2016 ACR/ARHP Annual Meeting
Mortality Rate According to Cause in Patients with Hemophagocytic Lymphohistiocytosis: A Meta-Analysis
Khushboo Sheth^1,2, Chia-Ling Kuo³, Dhruv Modi⁴ and Christopher Scola⁵, ¹Internal Medicine, University of Connecticut, Farmington, CT, Farmington, CT, ²Rheumatology, Stanford University, Palo Alto, CA, ³Department of Community Medicine and Health Care, University of Connecticut, Farmington, CT, ⁴Internal Medicine, Jamaica Hospital and Medical Center, New York, NY, ⁵Rheumatology, Hartford Hospital, Hartford, CT
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare syndrome of excessive immune activation associated with high mortality. Early diagnosis and treatment can reduce mortality among these patients.…
Abstract Number: 2620 • 2016 ACR/ARHP Annual Meeting
Retrospective Analysis for Determining the Signs and Symptoms of Infections before They Become Serious in Tocilizumab-Treated RA Patients Using a Postmarketing Adverse Events Reporting Database
Tatsuya Atsumi¹, Yoshiaki Ando², Yukiko Hayashi², Shinichi Matsuda², Riwa Tanaka², Nobuhiro Takagi² and Ayako Nakasone², ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Chugai Pharmaceutical Co. Ltd., Tokyo, Japan
Background/Purpose: Given that tocilizumab (TCZ) directly inhibits IL-6 signaling and strongly suppresses the inflammatory reaction, there is concern that the signs and symptoms associated with…
Abstract Number: 1195 • 2016 ACR/ARHP Annual Meeting
Risk of Hospitalized Infection Among Patients with Sarcoidosis: A Population-Based Retrospective Cohort Study
Patompong Ungprasert¹, Cynthia S. Crowson² and Eric L. Matteson¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN
Risk of Hospitalized Infection Among Patients With Sarcoidosis: A Population-Based Retrospective Cohort Study Background/Purpose: Increased risk of infection has been observed in several autoimmune disorders. …
Abstract Number: 2625 • 2016 ACR/ARHP Annual Meeting
Safety of Multiple Retreatments with Rituximab in Real Life: Long Term Registry Data from 1984 Patients with Rheumatoid Arthritis
Jacques-Eric Gottenberg¹, Philippe Ravaud², Thomas Bardin³, Alain Cantagrel⁴, Bernard Combe⁵, Maxime Dougados⁶, RENE MARC FLIPO⁷, Olivier Vittecoq⁸, Thierry Schaeverbeke⁹, Isabelle Pane¹⁰, Jean Sibilia¹¹, Xavier Mariette¹² and on behaf of all of the investigators of the AIR registry and of the French Society of Rheumatology , ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Epidemiology, Hotel Dieu, PARIS, France, ³Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, ⁴Rheumatology, INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Purpan Teaching Hospital, Toulouse, France, ⁵Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁶Rheumatology, Paris Descartes University, Paris, France, ⁷Rheumatology, Department of Rheumatology, CHU Teaching Hospital Lille, France., Lille, France, ⁸INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, ⁹Rheumatology, CHU Bordeaux, Bordeaux, France, ¹⁰Epidemiology, Hotel Dieu, Paris, France, ¹¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹²Institut National de la Santé et de la Recherche Médicale, Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France
Background/Purpose: Data are very limited concerning the safety of multiple retreatments with rituximab (RTX) in rheumatoid arthritis in common practice. Methods: This is a multicenter…
Abstract Number: 1311 • 2016 ACR/ARHP Annual Meeting
Causative Pathogens, Antibiotic Susceptibility, and Characteristics of Patients with Bacterial Septic Arthritis over Time
Sadao Jinno¹, Carol Sulis² and Maureen Dubreuil^3,4, ¹Rheumatology, Boston University School of Medicine, Boston, MA, ²infectious disease, Boston University School of Medicine, Boston, MA, ³Rheumatology, Boston VA HealthCare System, Boston, MA, ⁴Clinical Epidemiology, Boston University School of Medicine, Boston, MA
Background/Purpose: Management of septic arthritis remains a challenge. The emergence of methicillin-resistant Staphylococcus aureus (MRSA) strains with reduced vancomycin susceptibility and multi drug resistant (MDR)…
Abstract Number: 2643 • 2016 ACR/ARHP Annual Meeting
Risk Factors of Pneumocystis Jiroveci Pneumonia (PJP) in Patients with RA and Sulfasalazine As a Possible Protective Agent
Shinji Motojima¹, Tamao Nakashita², Akira Jibatake¹, Akira Yoshida¹ and Yoshiki Yamamoto¹, ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan, ²Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa-city, Japan
Background/Purpose: Pneumocystis jiroveci pneumonia (PJP) is a serious complication during the treatment in patients with variety of rheumatic disease. Postmarketing surveillance of infliximab and etnercept…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].